<code id='8CC119D756'></code><style id='8CC119D756'></style>
    • <acronym id='8CC119D756'></acronym>
      <center id='8CC119D756'><center id='8CC119D756'><tfoot id='8CC119D756'></tfoot></center><abbr id='8CC119D756'><dir id='8CC119D756'><tfoot id='8CC119D756'></tfoot><noframes id='8CC119D756'>

    • <optgroup id='8CC119D756'><strike id='8CC119D756'><sup id='8CC119D756'></sup></strike><code id='8CC119D756'></code></optgroup>
        1. <b id='8CC119D756'><label id='8CC119D756'><select id='8CC119D756'><dt id='8CC119D756'><span id='8CC119D756'></span></dt></select></label></b><u id='8CC119D756'></u>
          <i id='8CC119D756'><strike id='8CC119D756'><tt id='8CC119D756'><pre id='8CC119D756'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          fashion

          author:explore    - browse:9243
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot